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Aims Transcatheter aortic valve implantation (TAVI) is an established treatment alternative to surgical aortic valve replace-
ment in high-risk and inoperable patients and outcomes among patients with estimated low or intermediate risk
remain to be determined. The aim of this study was to assess clinical outcomes among patients with estimated
low or intermediate surgical risk undergoing TAVI.
Methods
and results
Between August 2007 and October 2011, 389 consecutive patients underwent TAVI and were categorized according
to the Society of Thoracic Surgeons (STS) score into low (STS , 3%; n ¼ 41, 10.5%), intermediate (STS ≥3% and
≤8%, n ¼ 254, 65.3%), and high-risk (STS . 8%; n ¼ 94, 24.2%) groups for the purpose of this study. Significant dif-
ferences were found between the groups (low risk vs. intermediate risk vs. high risk) for age (78.2+6.7 vs.
82.7+ 5.7 vs. 83.7+4.9, P, 0.001), body mass index (28.1+ 6.1 vs. 26.5+4.9 vs. 24.4+4.6, P, 0.001),
chronic renal failure (34 vs. 67 vs. 90%, P, 0.001), all-cause mortality at 30 days (2.4 vs. 3.9 vs. 14.9%,
P ¼ 0.001), and all-cause mortality at 1 year (10.1 vs. 16.1 vs. 34.5%, P ¼ 0.0003). No differences were observed
with regards to cerebrovascular accidents and myocardial infarction during 1-year follow-up.
Conclusion In contemporary practice, TAVI is not limited to inoperable or STS-defined high-risk patients and should be guided by
the decision of an interdisciplinary Heart Team. Compared with patients at calculated high risk, well-selected patients
with STS-defined intermediate or low risk appear to have favourable clinical outcomes.
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Introduction
Untreated symptomatic severe aortic stenosis has a dismal progno-
sis.1 A pharmacological treatment approach to relieve the mechan-
ical obstruction of the left ventricle or to slow progression of
disease has yielded disappointing results.2 For decades, surgical
aortic valve replacement (SAVR) was the only effective therapy
to alleviate symptoms and improve prognosis.3 After the first suc-
cessful transcatheter aortic valve implantation (TAVI) in 2002, pro-
spective trials4,5 and numerous observational studies6–8 have
reported improved survival of TAVI compared with medical treat-
ment in inoperable patients4 and similar outcomes compared with
SAVR in selected high-risk patients.5 Appropriate risk stratification
in patients referred for TAVI evaluation remains challenging, as
there is no validated risk score for TAVI patients and the currently
used surgical risk scores may over- or underestimate the actual risk
incurred.9 As a result, it is recommended to consider comorbid-
ities, and frailty in addition to calculated risk scores such as the
European System for Cardiac Operative Risk Evaluation (Euro-
SCORE) or Society of Thoracic Surgeons (STS) score, when
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evaluating the best therapeutic option for patients with severe
aortic stenosis.
Current guidelines recommend to perform TAVI in patients
considered inoperable or at high risk for SAVR.10 To appropriately
select elderly patients with symptomatic severe aortic stenosis, the
judgement of a collaborative group of physicians, including specia-
lists for cardiac surgery, interventional cardiology, cardiac anaes-
thesia as well as geriatric medicine, is warranted. Different
reasons affect the decision-making process and favour a less inva-
sive treatment strategy (TAVI) in contemporary clinical practice.
Factors including the general medical condition and frailty of the
patient importantly impact on treatment selection beyond the esti-
mated surgical risk as assessed by available risk scores. It is well
known that patients at high risk according to the STS score have
worse clinical outcome after SAVR compared with patients with
lower STS risk.11 However, little information is available on clinical
outcomes among patients undergoing TAVI deemed at low or
intermediate risk as assessed by surgical risk scores alone. Thus,
the purpose of the present study was to compare clinical out-
comes of patients undergoing TAVI considered at intermediate




Between August 2007 and October 2011, 389 elderly patients with
symptomatic severe aortic stenosis were included into a prospective
single centre registry (Bern TAVI Registry). Consecutive patients
underwent TAVI with the self-expandable Medtronic CoreValve bio-
prosthesis (MCV; Medtronic, Minneapolis, MN, USA) or the
balloon-expandable Edwards Sapien transcatheter heart valve (ES,
Edwards LifeSciences, Irvine, CA, USA), using the femoral, transapical,
and subclavian access route, as previously described.12 Decisions
regarding the access site were based on the individual anatomical char-
acteristics as determined by contrast enhanced computed tomography,
angiography, and transthoracic- or transoesophageal echocardiog-
raphy. The preferred access route followed the principle of the least
invasive approach. The study complied with the declaration of Helsinki,
and the registry was approved by the local ethics committee. All
patients provided written informed consent to participate in the regis-
try with prospective follow-up assessment.
The Heart Team decision
Patients referred for TAVI evaluation underwent interdisciplinary dis-
cussion in the local, institutional Heart Team consisting of experienced
interventional cardiologists and cardiovascular surgeons. The indica-
tion to undergo TAVI was based on patients’ clinical history (e.g. pre-
vious coronary artery bypass graft surgery, previous myocardial
infarction, previous cerebrovascular event), clinical status (e.g. body
mass index, diabetes mellitus, renal failure, left ventricular ejection frac-
tion, coronary artery disease, chronic obstructive lung disease), and a
dedicated geriatric assessment.13
Definitions
Clinical risk estimation was followed by prospective calculation of the
logistic EuroSCORE14 and the STS risk score.11 For the purpose of this
analysis, patients were categorized into three groups according to the
primarily proposed definition for the European SURTAVI patient
population15,16: (i) low-risk group (STS risk score, 3); (ii) intermedi-
ate risk group (STS risk score ≥3 and ≤8); and (iii) high-risk group
(STS risk score. 8). In addition, patients were subcategorized into
time quartiles according to treatment date and baseline clinical charac-
teristics and clinical outcomes subsequently analysed. All events were
adjudicated by an independent team of interventional cardiologists and
cardiac surgeons according to the endpoint definitions proposed by
the Valve Academic Research Consortium (VARC), described in
detail elsewhere.17
Statistical analysis
Patient demographics and follow-up data were prospectively collected
and entered into a dedicated database held at the Clinical Trials Unit,
University of Bern, Switzerland. All statistical analyses were performed
by a statistician of an academic clinical trials unit (D.H. and P.J., Depart-
ment of Clinical Research and Clinical Trials Unit Bern, Bern University
Hospital, Switzerland) using Stata 12 (StataCorp LP, College Station,
TX, USA). We report risk ratios (RR) (95% CI) from Mantel–Cox
log-rank tests of time to first event for death, cardiovascular death,
cerebrovascular accidents, and myocardial infarction up to 30-day
and 1-year follow-up separately. We report RR (95% CI) from
Poisson regressions with robust error variances for bleeding, acute
renal failure, access site complications, VARC safety endpoint, and
any composite involving these outcomes, occurring within 30 days
follow-up. We report RR (95% CI) derived from estimated probabil-
ities using exact logistic regressions in pair wise comparisons when
zero outcomes occurred in one of the risk groups. Overall P-values
show a test for a linear effect from the low to the intermediate to
the high STS risk groups, except Fisher’s test in case of zero
outcome in any risk group. The effect of STS risk score on all-cause
mortality at 1 year was analysed using logistic regression. Continuous
variables are presented as means+ SD and are compared by means
of analysis of variance F-tests. Categorical data are expressed as fre-




Out of 389 TAVI patients, 94 (24.2%) patients were categorized as
high risk (STS. 8), 254 patients (65.3%) as intermediate risk
(STS ≥ 3 and ≤8), and 41 (10.5%) patients as low risk (STS, 3).
Baseline clinical characteristics according to the risk group are sum-
marized in Table 1. Patients in the high-risk group were older, and
presented with lower body mass index compared with patients at
intermediate and low risk. Diabetes, arterial hypertension, peripheral
vascular disease, chronic obstructive pulmonary disease, and renal
failure were more prevalent among high risk compared with inter-
mediate and low-risk patients. There were no differences with
respect to previous myocardial infarction, previous coronary
artery bypass graft surgery, previous stroke, and atrial fibrillation
between the different patient groups. Left ventricular ejection frac-
tion was lower among high risk compared with intermediate and
low-risk patients (48.2+15 vs. 52.0+15 vs. 59.1+11, P,
0.001). Although we observed no differences in aortic valve area,
there was a trend towards a lower mean transaortic gradient
(41.6+19 vs. 44.4+16 vs. 48.6+16, P ¼ 0.08) and higher systolic
pulmonary arterial pressure (54.0+17 vs. 50.5+17 vs. 46.8+17,
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Table 1 Baseline clinical characteristics
All patients,
N5 389







Age (years) 82.5+5.8 78.2+6.7 82.7+5.7 83.7+4.9 ,0.001
Female gender, n (%) 224 (58%) 20 (49%) 145 (57%) 59 (63%) 0.31
Body mass index (kg/m2) 26.2+5.1 28.1+6.1 26.5+4.9 24.4+4.6 ,0.001
Cardiac risk factors
Diabetes mellitus, n (%) 105 (27%) 5 (12%) 66 (26%) 34 (36%) 0.01
Hypercholesterolaemia, n (%) 236 (61%) 25 (61%) 156 (62%) 55 (59%) 0.87
Hypertension, n (%) 303 (78%) 25 (61%) 203 (80%) 75 (80%) 0.02
Current smoker, n (%) 48 (12%) 6 (15%) 31 (12%) 11 (12%) 0.89
Past medical history
Previous myocardial infarction, n (%) 64 (16%) 5 (12%) 40 (16%) 19 (20%) 0.45
Previous coronary artery bypass graft, n (%) 72 (19%) 5 (12%) 43 (17%) 24 (26%) 0.10
Previous percutaneous coronary intervention, n (%) 94 (24%) 7 (17%) 59 (23%) 28 (30%) 0.24
Previous stroke, n (%) 30 (8%) 4 (10%) 17 (7%) 9 (10%) 0.59
Peripheral vascular disease, n (%) 87 (22%) 2 (5%) 52 (20%) 33 (35%) ,0.001
Chronic obstructive pulmonary disease, n (%) 72 (19%) 3 (8%) 43 (17%) 26 (28%) 0.01
Clinical features
Pulmonary artery hypertension (PAPs in mmHg) 51.0+17.0 46.8+16.7 50.5+16.9 54.0+17.2 0.06
Renal failure (GFR, 60mL/min/1.73 m2) 268 (69%) 14 (34%) 169 (67%) 85 (90%) ,0.001
Coronary artery disease, n (%) 238 (61%) 19 (46%) 155 (61%) 64 (68%) 0.06
Atrial fibrillation, n (%) 103 (27%) 6 (15%) 69 (27%) 28 (31%) 0.13
Echocardiographic variables
Left ventricular ejection fraction (%) 51.9+14.8 59.1+10.9 52.0+14.8 48.2+15.0 ,0.001
Aortic valve area (cm2) 0.6+0.2 0.6+0.2 0.6+0.2 0.6+0.2 0.97
Mean transaortic gradient (mmHg) 44.2+16.8 48.6+16.1 44.4+16.0 41.6+18.7 0.08
Symptoms
New York Heart Association (NYHA) Functional
Class
,0.001
I, n (%) 22 (6%) 8 (20%) 11 (4%) 3 (3%) ,0.001
II, n (%) 109 (28%) 20 (49%) 71 (28%) 18 (19%) 0.002
III, n (%) 206 (53%) 11 (27%) 146 (58%) 49 (53%) 0.001
IV, n (%) 49 (13%) 2 (5%) 24 (10%) 23 (25%) ,0.001
Heart Team decision ,0.001
Anatomical reasons, n (%) 12 (3%) 4 (10%) 7 (3%) 1 (1%) 0.02
Comorbidities with poor prognosis, n (%) 21 (5%) 2 (5%) 12 (5%) 7 (7%) 0.60
Intermediate surgical risk, n (%) 172 (44%) 25 (61%) 125 (49%) 22 (23%) ,0.001
Excessive surgical risk, n (%) 180 (46%) 10 (24%) 110 (43%) 60 (64%) ,0.001
Emergency intervention, n (%) 4 (1%) 0 (0%) 0 (0%) 4 (4%) 0.01
Risk assessment
Logistic EuroSCORE (%) 24.3+14.2 13.2+7.5 22.1+11.9 35.1+15.7 ,0.001
STS score (%) 6.8+5.3 2.1+0.5 5.1+1.4 13.3+7.1 ,0.001
Antithrombotic therapy at baseline
Aspirin, n (%) 237 (62%) 23 (56%) 152 (61%) 62 (67%) 0.45
Clopidogrel, n (%) 69 (18%) 4 (10%) 45 (18%) 20 (22%) 0.26
Oral anticoagulation, n (%) 106 (28%) 10 (24%) 68 (27%) 28 (30%) 0.77
PAPs, systolic pulmonary artery pressure.
Depicted are means+ SD with P-values from ANOVAs, or counts (%) with P-values from Chi-square (for multiple categories) or Fisher’s tests (for binary categories).
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P ¼ 0.06) among high risk compared with intermediate and low-risk
patients.
Baseline clinical characteristics were further analysed according
to time quartiles. STS risk assessment of patients was significantly
higher in the first quartile (Q1) compared with Q2 (7.5+5.9 vs.
5.6+ 4.7) but not different to Q3 and Q4 (Q3: 6.7+4.2; Q4:
7.3+ 5.8) (see Supplementary material online, Table S1).
Procedural results
Procedural characteristics and results are presented in Table 2. The
majority of patients underwent TAVI using the transfemoral access
route with either the Medtronic CoreValve (58%) or the Edwards
Sapien valve (42%) with no differences between the three risk
groups. Concomitant coronary revascularization tended to be
more frequently performed in high risk compared with the inter-
mediate and low surgical risk groups (22 vs. 15 vs. 7%, P ¼ 0.08).
As a result, the duration of the procedure (96.6+47 vs. 79.5+
30 vs. 70.5+23, P, 0.001) and fluoroscopy time (22.8+13 vs.
19.2+9 vs. 16.6+ 8, P ¼ 0.002) was highest among high-risk
patients.
Procedural characteristics according to time quartiles are
depicted in Supplementary material online, Table S2. Procedure
time (Q1 91.4+42 vs. Q4 70.7+ 28 min, P ¼ 0.001) as well as
the need for general anaesthesia (Q1 47 vs. Q4 26%, P ¼ 0.002)
significantly decreased over time. The VARC Device success stead-
ily increased (Q1 74 vs. Q4 97%, P, 0.001), which was mainly
related to a reduction in post-TAVI aortic regurgitation ≥2 (Q1
24 vs. Q4 2%, P, 0.001).
Clinical outcomes
Clinical outcomes at 30 days and at 1 year are summarized in
Table 3. All-cause mortality at 30 days was highest in the high-risk
group (14.9 vs. 3.9 vs. 2.4%, P ¼ 0.001), mainly driven by an
increased cardiovascular mortality (12.9 vs. 3.2 vs. 0%, P ¼
0.003). Major adverse events including acute renal failure (8.5 vs.
2.8 vs. 0%, P ¼ 0.03) and major access site complications (12.8
vs. 7.1 vs. 0%, P ¼ 0.03) were also more frequent in high risk com-
pared with intermediate and low-risk patients. There were no dif-
ferences with respect to cerebrovascular accidents, myocardial
infarction, and bleeding complications between the groups under-
going TAVI at 30 days of follow-up.
At 1 year of follow-up, all-cause mortality was highest among
high risk followed by intermediate and low-risk patients (34.5 vs.
16.1 vs. 10.1%, P ¼ 0.0003). The inter-group comparison demon-
strated a significant difference between the three groups (all-cause
mortality: low vs. high risk RR 0.27, 95%CI 0.09–0.77, intermediate
vs. high risk RR 0.41, 95% CI 0.24–0.67, P, 0.001; cardiovascular
mortality: low vs. high risk RR 0.16, 95% CI 0.04–0.70, intermedi-
ate vs. high risk RR 0.35, 95% CI 0.19–0.62, P ¼ 0.0001) (Figure 1).
All-cause mortality in this TAVI population followed a sigmoid
function with low rates of death in the low-risk group and an ex-
ponential increase up to the STS predicted risk of 25% (Figure 2,
logistic regression, STS risk score effect per 1 unit increase: OR
1.088, 95% CI 1.039–1.139, P ¼ 0.0003). No significant differences
with regards to cerebrovascular accidents and myocardial infarc-
tion between the different risk groups were observed throughout
1 year of follow-up.
Clinical outcomes at 30 days of follow-up per treatment quartile
are displayed in Supplementary material online, Table S3. The
inter-quartile group comparison showed no significant difference
for all-cause and cardiovascular death, major stroke, myocardial
infarction, and acute renal failure; however, there was a significant
reduction in life-threatening (Q1 23.5 vs. Q4 9.3%, RR 0.76,
95% CI 0.62–0.93, P ¼ 0.01) and major bleeding complications
(Q1 41.8 vs. Q4 18.6%, RR 0.78, 95% CI 0.68–0.88, P, 0.001).
Transfemoral transcatheter aortic valve
implantation
Out of 389 patients, 308 (79%) underwent TAVI via transfemoral,
76 (20%) patients via transapical, and 5 (1%) patients via transsub-
clavian access. Patients undergoing transfemoral TAVI were also
categorized into high risk, intermediate and low risk with baseline
clinical characteristics (Table 4) and clinical outcomes (Table 5)
shown separately. Among low-risk patients undergoing transfe-
moral TAVI, the 30-day rate of all-cause mortality, cerebrovascular
accidents, myocardial infarction, and acute renal failure was 0%.
Compared with the overall patient population, there was a linear
increase in all-cause (low vs. high risk RR 0.26, 95% CI 0.08–
0.90, intermediate vs. high risk RR 0.39, 95% CI 0.22–0.71,
P ¼ 0.0013) and cardiovascular mortality (low vs. high risk RR
0.21, 95% CI 0.05–0.91, intermediate vs. high risk RR 0.30,
95%CI 0.15–0.60, P ¼ 0.0005) at 1 year of follow-up.
Discussion
The present analysis of patients undergoing TAVI in the framework
of contemporary European practice has the following principal
findings:
† A substantial proportion of patients undergoing TAVI in con-
temporary clinical practice are at high-risk when calculating
the logistic EuroSCORE but only at intermediate risk when ap-
plying the STS score.
† Clinical outcomes among carefully selected patients considered
at low or intermediate risk according to the STS score are fa-
vourable and superior compared with high-risk patients.
† Transfemoral TAVI among patients with low STS score is asso-
ciated with the lowest rate of peri-procedural complications and
short-term mortality.
This analysis is based on a single-centre experience with consecu-
tive patients undergoing TAVI. All patients were considered to be
at increased risk for SAVR during the Heart Team discussion, but
were found to be at estimated intermediate risk when applying the
STS score. Significant comorbidities and high-risk features that are
not accounted for in the STS risk and EuroSCORE contribute to
this difference. This suggests that patient selection based on risk
score calculation only is not sufficient to assess the ‘true’ risk of
a patient undergoing SAVR. Thus, careful patient selection based
on the Heart Team model is required for appropriate treatment
allocation.10
Since the early stages of TAVI, the logistic EuroSCORE was
recommended as one of the surgical risk scores widely used in
Europe with a cut-off value of 20% considered as high risk. With
TAVI in low and intermediate risk patients 1897
growing experience in patient selection and in performing the pro-
cedure, it was recognized that the logistic EuroSCORE overesti-
mates the effective risk for adverse clinical outcomes.9 This
dilemma has led to inconsistent inclusion criteria across different
studies in the past. More recently initiated studies such as the
PARTNER 2 and the SURTAVI trial rely on a STS- rather than
EuroSCORE-based risk estimate. In the absence of a validated
risk score for patients undergoing TAVI, numerous factors includ-
ing comorbidities, clinical status, individual anatomical characteris-
tics, and frailty need to be carefully assessed and considered
prior to treatment allocation. The discussion of these factors in
a dedicated Heart Team is helpful to guide the most appropriate
patient selection and treatment allocation. In the present analysis,
we categorized patients into three different risk groups according
to the initial European inclusion criteria of the SURTAVI trial com-
paring TAVI with SAVR among intermediate risk patients (low-risk
STS score ,3%, intermediate risk 3–8%, high risk .8%). Consid-
ering the estimated risk of the overall population, this is well in line
with previous observational studies6,18 and reflects contemporary
practice in Europe. More recently, a single surgical centre in
Germany reported on a shift towards the treatment of lower
risk patients undergoing TAVI.19 Among 420 patients undergoing
TAVI at this institution, the overall calculated peri-operative risk
according to the STS score was 7.1+ 5.4% (EuroSCORE
25.4%+16) in the first quartile but only 4.8+2.6% (EuroSCORE
17.8+ 12%) in the last quartile of their experience. The trend
towards inclusion of lower risk patients is further substantiated
by a recent publication of the UK TAVI Registry investigators.20
Using the logistic EuroSCORE, the authors report an estimated
peri-operative risk of 18.5% (11.7–27.9), which is comparable
with the intermediate risk group [logistic EuroSCORE 19.6%
(12.8–28.7)] of the present patient population.
The present analysis revealed significantly better short- and
mid-term clinical outcomes of low and intermediate risk patients
compared with the high-risk group. All-cause and cardiovascular
mortality correlated well with the predicted risk according to
the STS score. Mortality followed a linear function at 30 days
and 1 year for cardiovascular and all-cause death in favour of
low and intermediate risk patients. Considering the VARC com-
bined safety endpoint, the low-risk group had a 59% and the inter-
mediate risk group a 45% lower risk to reach this endpoint
compared with the high-risk group. Moreover, the improved clin-
ical outcome for lower risk patients was sustained over time, dem-
onstrating a 71 and 59% relative risk reduction, respectively. Similar
results were reported from the German Heart Center in Munich,
with better clinical outcomes over time related to the inclusion of
lower risk and younger patients. The 30-day and 6-month mortality
rates decreased from 11.4 to 3.8% and from 23.5 to 12.4%,
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Table 2 Procedural characteristics
STS risk group P-value
All patients,
N 5 389
Low, N 5 41 Intermediate,
N5 254
High, N 5 94
Procedure time (min) 82.7+35.4 70.5+23.1 79.5+30.2 96.6+47.2 ,0.001
Fluoroscopy time (min) 19.8+10.3 16.6+7.8 19.2+9.3 22.8+13.1 0.002
Amount of contrast (mL) 252.2+96.7 226.0+82.0 255.9+94.1 254.0+108.1 0.18
General anaesthesia, n (%) 164 (42%) 17 (41%) 102 (40%) 45 (48%) 0.43
Access route
Transfemoral, n (%) 308 (79%) 33 (80%) 200 (79%) 75 (80%) 0.94
Transapical, n (%) 76 (20%) 8 (20%) 50 (20%) 18 (19%)
Transsubclavian, n (%) 5 (1%) 0 (0%) 4 (2%) 1 (1%)
Valve type
Medtronic CoreValve, n (%) 224 (58%) 25 (61%) 148 (58%) 51 (54%) 0.72
Edwards Sapien valve, n (%) 165 (42%) 16 (39%) 106 (42%) 43 (46%)
Revascularization
Concomitant PCI, n (%) 63 (16%) 3 (7%) 39 (15%) 21 (22%) 0.08
Staged PCI, n (%) 35 (9%) 1 (2%) 25 (10%) 9 (10%) 0.30
Procedural specifications
VARC device success, n (%) 330 (85%) 37 (90%) 216 (85%) 77 (82%) 0.46
Post TAVI—need for permanent pacemaker,
n (%)
97 (25%) 10 (24%) 67 (26%) 20 (21%) 0.62
Post TAVI—aortic regurgitation ≥2 52 (13%) 4 (10%) 33 (13%) 15 (16%) 0.60
Valve in series, n (%) 7 (2%) 0 (0%) 4 (2%) 3 (3%) 0.40
Depicted are means+ SD with P-values from ANOVAs or counts (%) with P-values from Chi-square (for multiple categories) or Fisher’s tests (for binary categories).
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Table 3 Clinical outcomes at 30 days and 1 year of follow-up
All patient, N 5 389 STS risk group Low vs. high Intermediate vs. high Overall P-value
Low, N 5 41 Intermediate, N5 254 High, N 5 94 RR (95% CI) RR (95% CI)
30 days follow-up
All-cause death, n (%) 24 (6.4) 1 (2.4) 10 (3.9) 13 (14.9) 0.16 (0.02–1.27) 0.27 (0.12–0.61) 0.001
Cardiovascular death, n (%) 19 (5.2) 0 (0.0) 8 (3.2) 11 (12.9) 0.06 (0.00–2.67) 0.25 (0.10–0.63) 0.003
Cerebrovascular accidents, n (%) 14 (3.6) 1 (2.4) 10 (4.0) 3 (3.4) 0.73 (0.08–7.07) 1.22 (0.34–4.43) 0.95
Major stroke, n (%) 12 (3.1) 1 (2.4) 8 (3.2) 3 (3.4) 0.73 (0.08–7.07) 0.97 (0.26–3.65) 0.83
Minor stroke, n (%) 2 (0.5) 0 (0.0) 2 (0.8) 0 (0.0) 2.14 (0.04–108.59) 1.00
Transient ischaemic attack, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Myocardial infarction, n (%) 2 (0.5) 0 (0.0) 1 (0.4) 1 (1.1) 0.50 (0.00–50.35) 0.37 (0.02–5.91) 0.57
Bleeding
Life-threatening, n (%) 64 (16.5) 6 (14.6) 36 (14.2) 22 (23.5) 0.63 (0.27–1.43) 0.61 (0.38–0.97) 0.10
Major, n (%) 125 (32.2) 12 (29.3) 79 (31.1) 34 (36.3) 0.81 (0.47–1.40) 0.86 (0.62–1.19) 0.35
Acute renal failure, n (%) 15 (3.9) 0 (0.0) 7 (2.8) 8 (8.5) 0.08 (0.00–3.40) 0.32 (0.12–0.87) 0.03
Access site complications
Major, n (%) 30 (7.7) 0 (0.0) 18 (7.1) 12 (12.8) 0.19 (0.03–1.30) 0.56 (0.28–1.11) 0.03
Minor, n (%) 42 (10.8) 8 (19.5) 27 (10.6) 7 (7.5) 2.62 (1.02–6.75) 1.43 (0.64–3.17) 0.06
VARC combined safety endpoint, n (%) 104 (26.8) 7 (17.1) 58 (22.8) 39 (41.6) 0.41 (0.20–0.84) 0.55 (0.40–0.77) 0.0004
All-cause death or stroke, n (%) 32 (8.2) 2 (4.9) 15 (5.9) 15 (16.0) 0.29 (0.07–1.27) 0.36 (0.18–0.74) 0.01
All-cause death, stroke, or MI, n (%) 34 (8.7) 2 (4.9) 16 (6.3) 16 (17.1) 0.27 (0.06–1.17) 0.36 (0.18–0.72) 0.004
1-year follow-up
All-cause death, n (%) 66 (19.6) 4 (10.1) 35 (16.1) 27 (34.5) 0.27 (0.09–0.77) 0.41 (0.24–0.67) 0.0003
Cardiovascular death, n (%) 48 (14.2) 2 (5.3) 24 (10.8) 22 (28.6) 0.16 (0.04–0.70) 0.35 (0.19–0.62) 0.0001
Cerebrovascular accidents, n (%) 18 (5.2) 3 (8.7) 12 (5.0) 3 (3.4) 2.00 (0.36–11.11) 1.42 (0.40–5.08) 0.38
Major stroke, n (%) 15 (4.3) 3 (8.7) 9 (3.6) 3 (3.4) 2.00 (0.36–11.11) 1.07 (0.29–3.99) 0.42
Minor stroke, n (%) 2 (0.5) 0 (0.0) 2 (0.8) 0 (0.0) na 2.14 (0.04–108.59) 1.00
Transient ischaemic attack, n (%) 1 (0.4) 0 (0.0) 1 (0.6) 0 (0.0) na 0.01 (0.00–0.08) 1.00
Myocardial infarction, n (%) 5 (1.6) 1 (3.1) 1 (0.4) 3 (4.3) 0.56 (0.05–6.31) 0.12 (0.01–1.04) 0.23
All-cause death or stroke, n (%) 77 (22.6) 7 (18.2) 41 (18.5) 29 (36.9) 0.44 (0.19–1.01) 0.45 (0.28–0.73) 0.0037
All-cause death, stroke, or MI, n (%) 79 (23.1) 8 (21.0) 41 (18.4) 30 (37.7) 0.48 (0.22–1.06) 0.43 (0.27–0.69) 0.0041
Depicted are counts (incidence rates %) and P-values for an overall linear effect.
Risks ratios (RR) (95% CI) from Mantel–Cox log rank for death, cardiovascular death, cerebrovascular events, myocardial infarction, and their composites.
Risk ratios (RR) (95% CI) derived from estimated probabilities using exact logistic regression in pair wise comparisons involving zero outcomes.











respectively, in a crude analysis comparing the first quartile treating
higher risk (STS 7.1%) vs. the last quartile with lower risk patients
(STS 4.8%). After adjustment for baseline differences, a trend
towards a more favourable 30-day clinical outcome was reported.
The treatment of severe aortic stenosis in low and intermediate
risk patients was recently addressed by the OBSERVANT research
group.21 Focusing on clinical outcomes, the authors performed a
propensity-score matched analysis of 266 patients undergoing
SAVR or TAVI. In this group, the preoperative risk assessment
was performed by using the logistic EuroSCORE which amounted
to 9.4+10.4% for SAVR and 8.9+9.5% among TAVI patients.
Mortality at 30 days amounted to 3.8% in patients undergoing
TAVI and SAVR and was similar when compared with the inter-
mediate risk patient population included into the present study.
Another single-centre study reported clinical outcomes of patients
categorized according to the logistic EuroSCORE and observed a
low 30-day mortality of 0.9% in the lowest risk patient population
(EuroSCORE, 15%).22
Figure 1 Cumulative incidence of all-cause mortality (A) and cardiovascular mortality (B) among patients with low (red line, STS score ,3),
intermediate (black line, STS score 3–8), and high surgical risk (red line, STS score. 8).
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The findings of the present and previous studies suggest that
patients with low or intermediate risk as assessed by the STS
score may undergo TAVI with a 30-day mortality of ,5%. These
results may be attributed to the continuous refinement of tech-
nique, equipment, and increasing operator experience.
Young patients at low surgical risk undergoing SAVR have 30-day
mortality rates as low as 0%,23 whereas elderly patients undergoing
isolated SAVR have mortality rates up to 6.7% in patients aged 80–
84 years, and up to 11.7% in those aged .85 years.24–26 Clinical
outcomes of the present study compare favourably with published
results of SAVR. Of note, all patients included into this study were
considered to be at increased surgical risk after multi-disciplinary
Heart Team discussion.
Apart from the low mortality among patients with low or inter-
mediate surgical risk according to the STS risk score, peri-
procedural complications including the VARC combined safety
endpoint were also less common. Compared with high-risk
patients, patients at low-or intermediate risk had significantly
lower rates of major bleeding, major vascular complications, and
deterioration of renal function. Especially, the rates of access site
and bleeding complications after TAVI have been a matter of
debate, and numerous efforts have aimed to minimize these
risks. Important advances in the pre-procedural assessment, includ-
ing semi-automated, CT-scan-based, post-processing software to
assist in device and access site selection, a further reduction in vas-
cular delivery sheath diameter, and refinements in suture-based
vascular closure devices have contributed to the favourable
results. Another matter of concern has been the high rate of per-
manent pacemaker implantation and paravalvular aortic regurgita-
tion after TAVI, which is not described after SAVR. While recent
evidence suggest that the need for permanent pacemaker implant-
ation after TAVI is not associated with worse clinical outcomes,27
post-procedural aortic regurgitation ≥2 is considered to have an
impact on mortality.28 Whether future generation TAVI prosthesis
with improved frame and valve designs as well as refinements in
implantation and positioning techniques might reduce the need
of a permanent pacemaker implantation and further reduce the
rate of relevant residual aortic regurgitation needs to be investi-
gated in the near future.
In a subgroup of patients undergoing transfemoral TAVI, the
30-day complication rate was remarkably low. Low-risk patients
undergoing transfemoral TAVI showed the most favourable
results with no events in terms of all-cause mortality, cerebrovas-
cular accidents, myocardial infarction, major access site complica-
tions, and acute renal failure 30 days after the intervention.
However, the relatively small patient number as well as the
primary intention to treat patients with the transfemoral access
route needs to be acknowledged when interpreting these results.
Nevertheless, transfemoral access is considered the least invasive
approach to perform TAVI, and can be performed as fully percu-
taneous procedure under local anaesthesia with mild sedation in
experienced centres.29 While the low rates of peri-procedural
complications in low and intermediate risk patients are promising,
the issue of cerebrovascular adverse events has been a matter of
concern.5 While several coexisting conditions such as atrial fibrilla-
tion, concomitant cerebrovascular disease, and aortic arch ather-
oma may increase the risk of stroke independent of the
procedure among elderly patients undergoing TAVI, the procedure
itself is associated with a certain risk of thromboembolic complica-
tions. Various factors have been identified to contribute to the risk
of cerebral injury including the retrograde passage of the calcified
aortic valve,30 the advancement of the large bore catheter through
the aortic arch and the ascending aorta as well as the balloon aortic
valvuloplasty, and the deployment of the prosthesis.31
At this point in time, two clinical trials currently recruit inter-
mediate risk patients to directly compare outcomes of patients
undergoing SAVR or TAVI. The PARTNER II trial randomly
assigns patients at intermediate surgical risk to undergo either
SAVR or TAVI with the Edwards Sapien XT bioprosthesis (Clinical-
Trials.gov identifier NCT01314313). In addition, the SURTAVI Trial
presently recruits intermediate risk patients to undergo treatment
by SAVR or TAVI with the Medtronic CoreValve bioprosthesis and
Figure 2 Logistic regression curve for all-cause mortality at 30 days of follow-up depending on the STS risk score assessment.
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Table 4 Baseline clinical characteristics: TransFemoral transcatheter aortic valve implantation patients
All patients,
N5 308
STS risk group P-value
Low,N 5 33 Intermediate,
N5 200
High,N 5 75
Age (years) 83.3+4.8 79.5+4.3 83.5+4.7 84.1+4.8 ,0.001
Female gender, n (%) 188 (61%) 18 (55%) 122 (61%) 48 (64%) 0.65
Body mass index (kg/m2) 26.1+4.8 27.9+6.1 26.4+4.5 24.5+4.7 0.001
Cardiac risk factors
Diabetes mellitus, n (%) 80 (26%) 4 (12%) 50 (25%) 26 (35%) 0.04
Hypercholesterolaemia, n(%) 179 (58%) 18 (55%) 115 (57%) 46 (61%) 0.77
Hypertension, n (%) 239 (78%) 21 (64%) 158 (79%) 60 (80%) 0.12
Current smoker, n (%) 29 (9%) 3 (9%) 18 (9%) 8 (11%) 0.92
Past medical history
Previous myocardial infarction, n (%) 47 (15%) 4 (12%) 28 (14%) 15 (20%) 0.41
Previous coronary artery bypass graft, n (%) 51 (17%) 4 (12%) 29 (14%) 18 (24%) 0.13
Previous percutaneous coronary intervention, n
(%)
71 (23%) 3 (9%) 44 (22%) 24 (32%) 0.03
Previous stroke, n (%) 23 (7%) 3 (9%) 13 (7%) 7 (9%) 0.68
Peripheral vascular disease, n (%) 51 (17%) 1 (3%) 29 (14%) 21 (28%) 0.002
Chronic obstructive pulmonary disease, n (%) 56 (18%) 2 (6%) 32 (16%) 22 (29%) 0.006
Clinical features
Pulmonary artery hypertension (PAPs in mmHg) 51.4+16.8 46.4+16.4 50.9+16.4 54.9+17.3 0.04
Renal failure (GFR, 60mL/min/1.73 m2) 213 (69%) 13 (39%) 133 (67%) 67 (89%) ,0.001
Coronary artery disease, n (%) 176 (57%) 13 (39%) 115 (57%) 48 (64%) 0.06
Atrial fibrillation, n (%) 84 (28%) 5 (15%) 56 (28%) 23 (33%) 0.17
Echocardiographic variables
Left ventricular ejection fraction (%) 52.3+14.6 59.8+10.4 52.6+14.5 48.4+15.0 0.001
Aortic valve area (cm2) 0.6+0.2 0.6+0.2 0.6+0.2 0.6+0.2 0.94
Mean transaortic gradient (mmHg) 44.5+16.9 48.6+16.3 45.0+16.3 41.3+18.6 0.09
Symptoms
New York Heart Association (NYHA) Functional Class
NYHA I, n (%) 20 (7%) 7 (21%) 10 (5%) 3 (4%) ,0.001
NYHA II, n (%) 84 (27%) 16 (48%) 55 (28%) 13 (18%)
NYHA III, n (%) 165 (54%) 8 (24%) 118 (59%) 39 (53%)
NYHA IV, n (%) 37 (12%) 2 (6%) 16 (8%) 19 (26%)
Heart Team decision
Anatomical or technical reasons, n (%) 1 (0%) 0 (0%) 1 (1%) 0 (0%) ,0.001
Comorbidities with poor prognosis, n (%) 16 (5%) 2 (6%) 8 (4%) 6 (8%)
Intermediate surgical risk, n (%) 151 (49%) 23 (70%) 110 (55%) 18 (24%)
Excessive surgical risk, n (%) 135 (44%) 8 (24%) 81 (41%) 46 (61%)
Emergency intervention, n (%) 4 (1%) 0 (0%) 0 (0%) 4 (5%)
Risk assessment
Logistic EuroSCORE (%) 23.8+14.5 13.1+6.4 21.4+12.0 35.1+16.3 ,0.001
STS score (%) 6.9+5.4 2.3+0.4 5.2+1.4 13.5+7.3 ,0.001
Antithrombotic therapy
Aspirin, n (%) 185 (60%) 16 (48%) 120 (60%) 49 (66%) 0.22
Clopidogrel, n (%) 53 (17%) 3 (9%) 31 (16%) 19 (26%) 0.06
Oral anticoagulation, n (%) 84 (27%) 8 (24%) 55 (28%) 21 (28%) 0.90
PAPs, systolic pulmonary artery pressure.
Depicted are means+ SD with P-values from ANOVAs or counts (%) with P-values from Chi-square (for multiple categories) or Fisher’s tests (for binary categories).
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Table 5 Clinical outcomes of transfemoral transcatheter aortic valve implantation patients at 30 days and 1 year of follow-up
All patients, N 5 308 STS risk group Low vs. high Intermediate vs. high Overall P-value
Low, N 5 33 Intermediate, N 5 200 High, N 5 75 RR (95% CI) RR (95% CI)
30 days follow-up
All-cause death, n (%) 17 (5.8) 0 (0.0) 7 (3.5) 10 (14.7) 0.05 (0.00–2.96) 0.24 (0.09–0.65) 0.006
Cardiovascular death, n (%) 14 (4.9) 0 (0.0) 5 (2.5) 9 (13.4) 0.03 (0.00–6.16) 0.19 (0.06–0.58) 0.004
Cerebrovascular events, n (%) 12 (3.9) 0 (0.0) 9 (4.5) 3 (4.2) 0.50 (0.05–5.17) 1.11 (0.30–4.12) 0.60
Major stroke, n (%) 10 (3.3) 0 (0.0) 7 (3.5) 3 (4.2) 0.36 (0.02–5.77) 0.86 (0.22–3.32) 0.78
Minor stroke, n (%) 2 (0.7) 0 (0.0) 2 (1.0) 0 (0.0) 2.13 (0.04–105.43) 1.00
Transient ischaemic attack, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Myocardial infarction, n (%) 1 (0.3) 0 (0.0) 0 (0.0) 1 (1.3) 0.23 (0.00–149.78) 37.50 (5.33–264.05) 0.35
Bleeding
Life-threatening, n (%) 40 (13.0) 4 (12.1) 21 (10.5) 15 (20.1) 0.61 (0.22–1.69) 0.53 (0.29–0.96) 0.14
Major, n (%) 97 (31.5) 9 (27.3) 62 (31.0) 26 (34.8) 0.79 (0.42–1.49) 0.89 (0.62–1.30) 0.42
Acute renal failure, n (%) 10 (3.2) 0 (0.0) 3 (1.5) 7 (9.4) 0.02 (0.00–44.54) 0.16 (0.04–0.61) 0.007
Access site complications
Major, n (%) 26 (8.4) 0 (0.0) 15 (7.5) 11 (14.7) 0.16 (0.02–1.38) 0.51 (0.25–1.06) 0.025
Minor, n (%) 41 (13.3) 8 (24.2) 26 (13.0) 7 (9.4) 2.60 (1.03–6.58) 1.39 (0.63–3.08) 0.06
VARC combined safety endpoint, n (%) 77 (25.0) 4 (12.1) 41 (20.5) 32 (42.8) 0.28 (0.11–0.74) 0.48 (0.33–0.70) 0.0001
All-cause death or stroke, n (%) 23 (7.5) 0 (0.0) 11 (5.5) 12 (16.1) 0.08 (0.00–1.49) 0.34 (0.15–0.76) 0.005
All cause death, stroke, or MI, n (%) 24 (7.8) 0 (0.0) 11 (5.5) 13 (17.4) 0.07 (0.00–1.45) 0.31 (0.14–0.69) 0.002
1-year follow-up
All-cause death, n (%) 48 (18.2) 3 (9.3) 25 (14.8) 20 (32.3) 0.26 (0.08–0.90) 0.39 (0.22–0.71) 0.0013
Cardiovascular death, n (%) 35 (13.2) 2 (6.3) 16 (9.3) 17 (27.7) 0.21 (0.05–0.91) 0.30 (0.15–0.60) 0.0005
Cerebrovascular events, n (%) 14 (5.0) 2 (7.7) 9 (4.5) 3 (4.2) 1.20 (0.16–8.81) 1.11 (0.30–4.12) 0.76
Major stroke, n (%) 12 (4.3) 2 (7.7) 7 (3.5) 3 (4.3) 1.20 (0.16–8.81) 0.86 (0.22–3.32) 0.84
Minor stroke, n (%) 2 (0.7) 0 (0.0) 2 (1.0) 0 (0.0) 2.13 (0.04–105.43) 1.00
Transient ischaemic attack, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Myocardial infarction, n (%) 4 (1.7) 1 (3.8) 0 (0.0) 3 (5.3) 0.54 (0.05–6.11) 0.34 (0.05–2.43) 0.018
All-cause death or stroke, n (%) 56 (21.0) 5 (16.3) 29 (16.7) 22 (35.2) 0.38 (0.14–1.04) 0.42 (0.24–0.74) 0.0053
All-cause death, stroke, or MI, n (%) 58 (21.7) 6 (19.8) 29 (16.7) 23 (36.0) 0.43 (0.17–1.10) 0.39 (0.23–0.68) 0.0058
Depicted are counts (incidence rates %) and P-values for an overall linear effect.
Risks ratios (RR) (95% CI) from Mantel–Cox log rank for death, cardiovascular death, cerebrovascular events, myocardial infarction, and their composites.
Risk ratios (RR) (95% CI) from Poisson regression with robust error variances for bleeding, acute renal failure, access site complications, VARC safety endpoint, and any composite involving these outcomes.
Risk ratios (RR) (95% CI) derived from estimated probabilities using exact logistic regression in pair wise comparisons involving zero outcomes.











will provide additional important information regarding this issue
(ClinicalTrials.gov identifier NCT01586910).
Limitations
When interpreting the results of this study, a number of limitations
need to be acknowledged. First, patients underwent treatment in a
single, tertiary care referral centre and results may not be general-
izable to all institutions. Second, patients were retrospectively
categorized into three different risk groups (low, intermediate,
and high surgical risk) based on the STS score. This categorization
ignores the clinical judgment as well as treatment allocation based
on recommendations of the Heart Team introducing an important
element of selection bias. Third, differences in baseline character-
istics including age and comorbidities outweigh the importance of
procedural outcomes during the longer term follow-up. Forth, the
study population is small and these findings require confirmation in
larger, prospective studies. Finally, the lack of long-term follow-up
data does not allow to draw conclusions about valve durability
which constitutes an important issue for lower risk and especially
younger patients.
Conclusion
In contemporary practice, TAVI is not limited to inoperable or
STS-defined high-risk patients and should be guided by the decision
of an interdisciplinary Heart Team. Compared with patients at cal-
culated high risk, well-selected patients with STS-defined inter-
mediate or low risk appear to have favourable clinical outcomes.
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Supplementary material is available at European Heart Journal
online.
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